| |
| |
| Accelerate Your Product’s Potential with Zydis® Rapid Dissolve Technology |
|
|
| 35 years ago, Catalent created the ODT market, and has been innovating ever since. Customers keep coming back to Zydis ODT for several reasons: |
|
|
| Patient Experience –Zydis ODT provides a smooth mouth feel, exceptional taste masking and dissolves in ~3s, without the need for water.
Convenience – Zydis tablets are durable, can be taken without water, and come individually blister-packaged, perfect for patients on the go. |
|
|
| Brand Strength – Companies leverage the advantages of Zydis, and the ODT format, to set their brands apart.
Innovation – Catalent has improved upon the best-in-class Zydis ODT with Zydis ULTRA, providing greater dose loading, taste-masking and functional coating, and Zydis BIO, supporting oral delivery of macromolecules.
|
|
|
| See how Zydis ODT unlocks patient preference in the following case study: |
|
|
| |
| The Right Technologies to Address
Patient Needs, Reliably Supplied |
|
|
| Catalent’s comprehensive approach to drug development coupled with the broadest selection of advanced drug delivery technologies and manufacturing platforms available enables us to match stakeholder considerations with the right solutions |
|
|
| Our broad range of advanced delivery technologies can address patient needs and challenges including, dose loading, taste masking, drug release, food effects and others. |
|
|
| |
| Executive Summary: Is My Molecule Suitable for an Orally Disintegrating Tablet? |
|
|
| Summary: Download this executive summary to learnwhy Orally Disintegrating Tablets (ODTs) are a patient-preferred dose form that offers additional potential benefits related to pregastric API delivery and absorption. While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products. |
|
|
| |
| Webinar: Strategies to Optimize the
Dosage Form Design Process to
Create Better Treatments |
|
|
| Summary: In this webinar, co-organized with Bionow, experts use case studies to demonstrate how the right guidance, at the right time, can help drug developers create better treatments. The experts discuss Catalent’s holistic development approach that combines the API’s biopharmaceutic properties, PBPK modeling, manufacturability, and target patient characteristics to support decision-making during the dosage form design process. |
|
|
| |
| |
| Every brand has a challenge. We have a solution.
|
|
|
| |
| or call +1 877 891 9609 to speak with one of our experts today!
|
|
|
